NCT00151437View on ClinicalTrials.gov

Canadian Pegvisomant Compassionate Study In Acromegalic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

April 30, 2007

Conditions
Acromegaly
Interventions
DRUG

Pegvisomant treatment

PROCEDURE

Medical History, demographics

PROCEDURE

Sign and symptoms: questionnaire

PROCEDURE

Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT

PROCEDURE

MRI

Trial Locations (5)

T6G 2B7

Pfizer Investigational Site, Edmonton

T6G 2S2

Pfizer Investigational Site, Edmonton

B3H 2Y9

Pfizer Investigational Site, Halifax

M5G 1X5

Pfizer Investigational Site, Toronto

H2L 2W5

Pfizer Investigational Site, Montreal

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00151437 - Canadian Pegvisomant Compassionate Study In Acromegalic Patients | Biotech Hunter | Biotech Hunter